## Interactions with Outpatient Medicines & Nirmatrelvir/ritonavir (NMV/r)

Please check [www.covid19-druginteractions.org](http://www.covid19-druginteractions.org) for updates.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website where possible.

### Interactions with Outpatient Medicines & Nirmatrelvir/ritonavir (NMV/r)

#### Charts revised 6 July 2022

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

### Interaction tables - refer to page 3 for legend, abbreviations and notes

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website where possible.

<table>
<thead>
<tr>
<th>Analgesics</th>
<th>Anticonvulsants</th>
<th>Antidiabetics</th>
<th>Anxiolytics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>Brivaracetam</td>
<td>Acarbose</td>
<td>Alprazolam</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Carbamazepine</td>
<td>Canagliflozin</td>
<td>Bromazepam</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>Clonazepam</td>
<td>Dapagliflozin</td>
<td>Buspirone</td>
</tr>
<tr>
<td>Codeine</td>
<td>Eslicarbazepine</td>
<td>Dulaglutide</td>
<td>Clozapam</td>
</tr>
<tr>
<td>Dextropropoxyphene</td>
<td>Ethosuximide</td>
<td>Empagliflozin</td>
<td>Clorazepate</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>Gabapentin</td>
<td>Exenatide</td>
<td>Diazepam</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Lacosamide</td>
<td>Glibenclamide</td>
<td>Estazolam</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>Lamotrigine</td>
<td>Gliclazide</td>
<td>Flunitrazepam</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>Levetiracetam</td>
<td>Glimipride</td>
<td>Flurazepam</td>
</tr>
<tr>
<td>Mefenamic acid</td>
<td>Oxcarbazepine</td>
<td>Glipizide</td>
<td>Lorazepam</td>
</tr>
<tr>
<td>Methadone</td>
<td>Phenobarbital</td>
<td>Insulin</td>
<td>Lormetazepam</td>
</tr>
<tr>
<td>Morphine</td>
<td>Phenytoin</td>
<td>Linagliptin</td>
<td>Midazolam</td>
</tr>
<tr>
<td>Naproxen</td>
<td>Pregabalin</td>
<td>Liraglutide</td>
<td>Oxazepam</td>
</tr>
<tr>
<td>Oxydode</td>
<td>Primidone</td>
<td>Metformin</td>
<td>Temazepam</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>Retigabine</td>
<td>Pioglitazone</td>
<td>Triazolam</td>
</tr>
<tr>
<td>Pethidine</td>
<td>Rufinamide</td>
<td>Rosiglitazone</td>
<td>Zaleplon</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>Tiagabine</td>
<td>Saxagliptin</td>
<td>Zopiclone</td>
</tr>
<tr>
<td>Tramadol</td>
<td>Topiramate</td>
<td>Sitagliptin</td>
<td>Beta blockers</td>
</tr>
<tr>
<td>Antiarhythmicsh</td>
<td>Valproate</td>
<td>Tolbutamide</td>
<td>Atenolol</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Vigabatin</td>
<td>Vildagliptin</td>
<td>Bisoprolol</td>
</tr>
<tr>
<td>Bepridil</td>
<td>Zonisamide</td>
<td>Ziramol</td>
<td>Carvedilol</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Antidepressants</td>
<td>Antipsychotics</td>
<td>Divalprool</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>Agomelatine</td>
<td>Amisulpride</td>
<td>Metoprolol</td>
</tr>
<tr>
<td>Dofetilide</td>
<td>Amitriptyline</td>
<td>Aripiprazole</td>
<td>Nebivolol</td>
</tr>
<tr>
<td>Dronedarone</td>
<td>Bupropion</td>
<td>Asenapine</td>
<td>Propranolol</td>
</tr>
<tr>
<td>Flecainide</td>
<td>Citalopram</td>
<td>Chlorpromazine</td>
<td>Sotalol</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Clomipramine</td>
<td>Clozapine</td>
<td>Timolol</td>
</tr>
<tr>
<td>Propafenone</td>
<td>Desipramine</td>
<td>Fluphenazine</td>
<td>Bronchodilators</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Desoximide</td>
<td>Haloperidol</td>
<td>Acidinium bromide</td>
</tr>
<tr>
<td>Anticoagulants/antiplatelets</td>
<td>Duloxetine</td>
<td>Iloperidone</td>
<td>Aminophylline</td>
</tr>
<tr>
<td>Apixaban</td>
<td>Escitalopram</td>
<td>Leomepromazine</td>
<td>Formoterol</td>
</tr>
<tr>
<td>Aspirin (antiplatelet)</td>
<td>Fluoxetine</td>
<td>Lumateperone</td>
<td>Glycopyrronium bromide</td>
</tr>
<tr>
<td>Clopidogrel (stented)</td>
<td>Impiramine</td>
<td>Lurasidone</td>
<td>Indacaterol</td>
</tr>
<tr>
<td>Dabigatran (b)</td>
<td>Lithium</td>
<td>Olanzapine</td>
<td>Ipratropium bromide</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>Maprotiline</td>
<td>Paliperidone</td>
<td>Montelukast</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>Mianserin</td>
<td>Pericizine</td>
<td>Olodaterol</td>
</tr>
<tr>
<td>Edoxaban (c)</td>
<td>Mirtazapine</td>
<td>Perphenazine</td>
<td>Offumilast</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Nortriptyline</td>
<td>Pimozide</td>
<td>Salbutamol</td>
</tr>
<tr>
<td>Heparin</td>
<td>Paroxetine</td>
<td>Pioglitazone</td>
<td>Salmeterol</td>
</tr>
<tr>
<td>Phenprocoumon (d)</td>
<td>Reboxetine</td>
<td>Risperidone</td>
<td>Theophylline</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Sertraline</td>
<td>Sulpiride</td>
<td>Tiotropium bromide</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>St John’s Wort</td>
<td>Triazolone</td>
<td>Umeclidinium bromide</td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>Trazodone</td>
<td>Tiapride</td>
<td>Vilanterol</td>
</tr>
<tr>
<td>Tinzaparin</td>
<td>Venlafaxine</td>
<td>Vortioxetine</td>
<td></td>
</tr>
<tr>
<td>Warfarin (d)</td>
<td>Vortioxetine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Interactions with Outpatient Medicines & Nirmatrelvir/ritonavir (NMV/r)

Please check [www.covid19-druginteractions.org](http://www.covid19-druginteractions.org) for updates.

**Interaction tables - refer to page 3 for legend, abbreviations and notes**

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website where possible.

### Contraceptives
- Norgestrel (COC)
- Levonorgestrel (IUD)
- Levonorgestrel (POP)
- Norethisterone (COC)
- Norethisterone (IM)
- Norethisterone (PO)
- Medroxyprogesterone (depot injection)

### Cancer drugs
- Abemaciclib (e)
- Acalabrutinib
- Acalabrutinib
- Abitibine
- Alectinib
- Alectinib
- Alpatumumab
- Atezolizumab
- Bosutinib
- Capcitabine
- Certitinib (a)
- Dasatinib (f)
- Encorafenib (e)
- Enzalutamide
- Erlotinib (e)
- Fostamatinib
- Gilteritinib (e)
- Ibrutinib (g)
- Imatinib
- Ivosidenib
- Lenalidomide
- Midostaurin (h)
- Neratinib
- Nilotinib (f)
- Olaparib (e)
- Olaparib (e)
- Palbociclib (e)
- Pazopanib (e)
- Pomalidomide
- Ribociclib (e)
- Sotorasib
- Sunitinib (e)
- Tamoxifen
- Venetoclax (l)
- Vinblastine (e)
- Vincristine (e)

### Contraceptives
- Desogestrel (COC)
- Desogestrel (POP)
- Ethinyl estradiol
- Etonogestrel (IMP)
- Etonogestrel (VR)
- Levonorgestrel (COC)
- Levonorgestrel (IUD)
- Levonorgestrel (POP)
- Medroxyprogesterone (depot injection)
- Norethisterone (COC)
- Norethisterone (IM)
- Norethisterone (PO)
- Norgestrel (COC)

### Cystic fibrosis agents
- ATV/CFTR
- CFTR modulators
- Suramin

### Cystic fibrosis agents
- Antacids
- Aprepitant
- Domperidone
- Esomeprazole
- Fatomidine
- Lansoprazole
- Loperamide
- Mesalazine
- Metoclopramide
- Omeprazole
- Ondansetron
- Pantoprazole
- Rabeprazole
- Ranitidine
- Seneca

### HCV antivirals
- Elna
- PEG-IFN
- Ribavirin

### HIV antiretrovirals
- Abacavir
- Atazanavir
- Bictegravir
- Cabotegravir
- Darunavir
- Dolutegravir
- Doravirine
- Elafavir
- Emtricitabine
- Efavirenz
- Emtricitabine
- Estazavir
- Lamiudavir
- Nevirapine
- Raltegravir
- Rilpivirine
- Tenofovir alafenamide
- Tenofovir DF

### Hypertension/heart failure
- Alikiren
- Ambrisentan
- Amiloride
- Bosentan
- Candesartan
- Captopril
- Clazapril
- Doxazosin
- Enalapril
- Eplerenone
- Eprosartan
- Fosinopril
- Furosemide
- Hydrochlorothiazide
- Hydroxychloroquine
- Iloprost
- Indapamide
- Irbesartan
- Ivabradine
- Labetalol
- Lacidipine
- Lercanidipine
- Lisinopril
- Losartan
- Olmesartan
- Perindopril
- Prazosin
- Quinapril
- Ramipril
- Ranolazine
- Riociguat (i)
- Sacubitril
- Sildenafil
- Spironolactone
- Taladilaf
- Telmisartan
- Terazosin
- Torsemide
- Trandolapril
- Valsartan

### Immunossuppressants
- Adalimumab
- Azathioprine
- B cell depleting agents
- Belatacept
- Ciclosporin (k)
- Etanercept
- Everolimus
- Leflunomide
- Methotrexate
- Mycophenolate
- Sirolimus
- Tacrolimus (l)
- Vincsospin

### Lipid lowering agents
- Atorvastatin
- Clofibrate
- Evolocumab
- Ezetimibe
- Fenofibrate
- Fluvastatin
- Gemfibrozil
- Lovastatin
- Pitavastatin
- Pravastatin
- Rosuvastatin
- Simvastatin

### Multiple sclerosis agents
- Alemtuzumab
- Baclofen
- Cladribine
- Dantrolene sodium
- Dimethyl fumarate
- Fampridine
- Fingolimod
- Glatiramer acetate
- Natalizumab
- Ocrelizumab
- Ozanimod
- Peginterferon beta-1a
- Siponimod
- Teriflunomide

### Others
- Alendronic acid
- Alizosin
- Aliporulin
- Calcium supplement
- Colchicine
- Donepezil
- Ergometrine (ergonovine)
- Ergotamine
- Fenasteride
- Hydroxychloroquine
- Infliximab
- Levodopa
- Levotroxyline
- Memantine
- Methotrexate
- Mirabegron (m)
- Modafinil
- Premipexole
- Pyridostigmine
- Rifabutin (n)
- Rifampin
- Rifampin
- Tamsulosin (o)

### Steroids
- Beclometasone
- Betamethasone
- Ciclesonide
- Clobetasol
- Fludrocortisone
- Fluorisole
- Fluticasone
- Hydrocortisone
- Methylprednisolone
- Mometasone
- Prednisolone
- Prednisone
- Triamcinolone

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants of agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.
We aim to ensure that in this publication whether

<table>
<thead>
<tr>
<th>Colour/Symbol</th>
<th>Recommendation for NMV/r use</th>
</tr>
</thead>
<tbody>
<tr>
<td>![ ]</td>
<td>Do not use NMV/r ⇒ alternative COVID-19 therapy</td>
</tr>
<tr>
<td>![ ]</td>
<td>Do not use NMV/r ⇒ alternative COVID-19 therapy</td>
</tr>
<tr>
<td>![ ]</td>
<td>NMV/r use ONLY possible if drug is paused or replaced by a non-interacting drug</td>
</tr>
<tr>
<td>![ ]</td>
<td>Potential interaction</td>
</tr>
<tr>
<td>![ ]</td>
<td>Dose adjustment and/or close monitoring required.</td>
</tr>
<tr>
<td>![ ]</td>
<td>Potential interaction</td>
</tr>
<tr>
<td>![ ]</td>
<td>Manageable by counselling patient</td>
</tr>
<tr>
<td>![ ]</td>
<td>Weak interaction</td>
</tr>
<tr>
<td>![ ]</td>
<td>No action needed</td>
</tr>
<tr>
<td>![ ]</td>
<td>No interaction expected</td>
</tr>
</tbody>
</table>

**Legend**

- **EC** = emergency contraception
- **COC** = combined oral contraceptive
- **IM** = intramuscular
- **IUD** = intrauterine device
- **IMP** = implant
- **POP** = progestin only contraceptive pill
- **VR** = vaginal ring

**Notes**

a) Ritonavir reduces the conversion to clopidogrel’s active metabolite leading to insufficient inhibition of platelet aggregation. Thus, it is recommended to avoid NMV/r in patients at very high-risk of thrombosis (e.g. early period post coronary stenting) unless clopidogrel can be switched to the non-interacting drug prasugrel. However, NMV/r treatment is possible in other clinical situations for which a transient loss in clopidogrel efficacy is acceptable (e.g. alternative to aspirin in intolerant patients).

b) When used for the treatment of atrial fibrillation, reduce dabigatran to 110 mg twice daily in individuals with normal renal function and to 75 mg twice daily in individuals with moderate renal impairment. Consult www.covid19-druginteractions.org for management in other indications.

c) When used for the treatment of atrial fibrillation, reduce edoxaban to 30 mg. Consult www.covid19-druginteractions.org for management in other indications.

d) Monitor INR as clinically indicated.

e) Decision to hold or dose adjust the cancer drug should be made in conjunction with the patient’s oncologist. Consult www.covid19-druginteractions.org for detailed information.

f) Accelerated or blast phase chronic myelogenous leukaemia: do not co-administer, use alternative COVID-19 therapy. In the indication of chronic phase chronic myelogenous leukaemia, the decision to hold or dose adjust the cancer drug should be made in conjunction with the patient’s oncologist. If it is decided to hold treatment, restart the cancer drug at least 3 days after completing NMV/r. Alternatively dose adjust, consult www.covid19-druginteractions.org for details.

g) The decision to hold ibrutinib treatment should be made in conjunction with the patient’s oncologist. It may be dangerous to interrupt therapy in patients with high volume chronic lymphocytic leukaemia or mantle cell lymphoma due to disease flare and/or cytokine release. Consider an alternative COVID-19 therapy.

h) Strong CYP3A4 inhibitors can substantially increase midostaurin exposure. Consider an alternative COVID-19 treatment.

i) Coadministration with NMV/r is contraindicated at initiation and during the dose-titration phase to minimize the risk of tumour lysis syndrome. Use an alternative COVID19 therapy.

j) The European product label for riociguat does not recommend its use in presence of strong inhibitors; the US product label recommends to start riociguat at a dose of 0.5 mg three times daily and to monitor for signs and symptoms of hypotension.

k) The management of this interaction is challenging and would require dosage adjustment and therapeutic drug monitoring (TDM) of cyclosporin which may not be possible given the short duration of NMV/r treatment. An alternative COVID treatment should be considered. However, if TDM is available, an empiric dose reduction of cyclosporin has been suggested (reduce total daily dose by 80% and administer once daily) during treatment with NMV/r (days 1-5). Cyclosporin concentrations should be assessed on day 6 or 7 and repeated every 2-4 days.

l) The management of this interaction is challenging and would require a substantial reduction in tacrolimus dosage. Considering the complex management of this interaction, an alternative COVID treatment will need to be considered. However, if TDM for tacrolimus is available, it has been suggested to withhold all tacrolimus doses during treatment with NMV/r (days 1-5). It is advised to measure tacrolimus concentrations on day 3 to assess the need for a one-time tacrolimus dose during NMV/r treatment. Tacrolimus concentrations should be assessed on day 6 or 7 (and every 2-4 days thereafter) and concentrations used to guide the continued witholding or gradual reintroduction of tacrolimus.

m) No dose reduction or monitoring in patients with normal renal function.

n) Rifabutin is dosed at 150 mg once daily with NMV/r.

o) Coadministration should be avoided. Pause tamsulosin and restart 3 days after completing nirmatrelvir/ritonavir. Alternatively, consider using tamsulosin 0.4 mg/day or every other day with monitoring for hypotension. The dose of tamsulosin should not exceed 0.4 mg/day if coadministered.